Reductions to variable extents were observed for TNF-alpha mRNA levels (~20–90%) and lung inflammation scores (~0–60%) depending on the disease process and the treatment, with efficacy against asthma models being less evident than for LPS induced inflammation models. Here, TNF is linked to asthma.